Ohio Doctor Loses DEA Registration After State Action
Published Date: 7/10/2026
Notice
Summary
Dr. Timothy Genetta from Ohio lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he must stop prescribing or handling these drugs immediately, with no money or timing benefits for him.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Genetta
The DEA revoked Timothy Genetta, D.O.'s Certificate of Registration No. FG3579503 after finding he is not licensed to practice medicine in Ohio and therefore not authorized to handle controlled substances. The Order also denies any pending applications to renew, modify, or obtain additional DEA registration in Ohio; the Order is effective August 10, 2026.
15-Day Reconsideration Opportunity
The Order states that the registrant may dispute the Agency's finding that he lacks a license by filing a properly supported motion for reconsideration within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email as described in the Order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-13991, Ruth Jones, D.O.; Decision and Order
Ruth Jones, D.O., tried to get a DEA registration but was denied because she was convicted of serious drug-related crimes and banned from federal health programs. She missed the deadline to ask for a hearing, so the case was closed against her. This means she can’t legally handle controlled substances, affecting her medical practice and career.
Next: 2026-13993, Certain Pre-Stretched Synthetic Braiding Hair and Packaging Therefor; Notice of Commission Determination Not To Review an Initial Determination Terminating the Enforcement Proceeding Based on Withdrawal of the Enforcement Complaint; Termination of the Enforcement Proceeding
JBS Hair decided to drop their complaint against Vivace about synthetic braiding hair, so the U.S. International Trade Commission ended the enforcement case. This means Vivace won’t face any penalties or restrictions related to this issue. If you’re in the hair product business, no changes or costs are coming from this case anymore.